C
Corvus Pharmaceuticals D
D
CRVS
4.70000
USD
-0.06
(-1.16%)
مغلق
حجم التداول
20,137
الربح لكل سهم
-0
العائد الربحي
-
P/E
-5
حجم السوق
362,438,789
الأخبار المقالات
العنوان: Corvus Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).